HKUOC

Phase 3 randomized, double-blind study in first-line ER+ (≥1%), HER2− advanced/metastatic breast cancer comparing palazestrant + ribociclib vs letrozole + ribociclib. Includes key inclusion/exclusion criteria and dosing details. Contact Hong Kong United Oncology Centre.

NCT07085767: OPERA-02 Study

Leave a Comment / breast cancer, PIK3CA gene, Breast cancer research, Breast cancer drugs, Targeted therapy, Hormone therapy /

The Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with estrogen receptor-positive (ER+), HER2-negative (HER2−) advanced/metastatic breast cancer, please contact us. We will conduct an initial assessment to determine if you meet the eligibility criteria for this clinical trial. Medication and imaging scan costs are fully covered. However, patients must understand the purpose of the study and the potential risks involved.

NCT07085767: OPERA-02 Study Read More »

癌症患者免疫力下降易生蛇，症狀包括神經痛、水泡，易與癌症痛症混淆。李宇聰醫生建議化療前接種新一代重組生蛇疫苗，非活體疫苗更安全，保護率87.7%，保護期11年。發病72小時內服抗病毒藥可減輕症狀。香港聯合腫瘤中心提供疫苗諮詢、接種及治療服務，助患者預防生蛇。

Cancer patients are prone to severe sequelae of snakes｜ Early vaccination reduces risk-Professional analysis by Dr. Li Yu Chung, Jacky

Leave a Comment / News report /

Cancer patients have reduced immunity and are prone to snakes. Symptoms include neuralgia and blisters, which are easily confused with cancer pain. Dr. Li Yu Chung, Jacky recommends that a new generation of recombinant snake vaccine be vaccinated before chemotherapy. Non-live vaccines are safer, with a protection rate of 87.7% and a protection period of 11 years. Taking antiviral drugs within 72 hours of the onset of the disease can reduce symptoms. The United Cancer Centre of Hong Kong provides vaccine consultation, vaccination and treatment services to help patients prevent cancer.

Cancer patients are prone to severe sequelae of snakes｜ Early vaccination reduces risk-Professional analysis by Dr. Li Yu Chung, Jacky Read More »

第四期肺癌康復奇蹟｜鍾喜英HER2基因突變成功治療個案 - 李宇聰醫生解析基因檢測重要性

Stage 4 Lung Cancer Recovery Miracle | A Successful Treatment Case of HER2 Gene Mutation

Leave a Comment / HER2 gene, Uncategorized, Targeted therapy, Lung cancer /

Ms. Zhong Xiying was diagnosed with multiple metastases of stage 4 lung cancer in the brain, liver and bone, and once wanted to give up treatment. Dr. Li Yu Chung, Jacky insisted on genetic testing to find rare HER2 mutations, and quickly formulated a personalized targeted treatment plan to successfully control the condition. Real cases share how genetic testing has changed destiny, and now Ms. Zhong can travel with her family and enjoy happiness. The United Cancer Centre of Hong Kong provides comprehensive genetic testing and personalized treatment services.

Stage 4 Lung Cancer Recovery Miracle | A Successful Treatment Case of HER2 Gene Mutation Read More »

台灣男星顏正國肺腺癌離世，確診不足1年。香港聯合腫瘤中心李宇聰醫生解析本港肺癌致命率達66%，每年5,707人確診。詳解6大高危人士、3種警號徵狀、4大治療方案及存活率。第一期治癒率達90%，及早篩查是關鍵。提供標靶治療、免疫治療及LDCT肺癌篩查服務。

Yen Cheng-kuo passed away from lung adenocarcinoma | Dr. Li Yu Chung, Jacky analyzes 6 high-risk factors, survival rates, and the latest treatment options

Leave a Comment / News report /

Taiwanese male star Yan Zhengguo passed away from pulmonary adenocarcinoma, less than 1 year after his diagnosis. According to an analysis by Dr. Li Yu Chung, Jacky of the United Cancer Centre of Hong Kong, the fatal rate of lung cancer in Hong Kong is 66%, with 5,707 people diagnosed each year. Detailed description of 6 high-risk persons, 3 warning signs, 4 treatment options and survival rates. The treatment rate in the first phase is 90%, and early screening is the key. Provide targeted therapy, immunotherapy and LDCT lung cancer screening services.

Yen Cheng-kuo passed away from lung adenocarcinoma | Dr. Li Yu Chung, Jacky analyzes 6 high-risk factors, survival rates, and the latest treatment options Read More »

李宇聰醫生主講「擁抱希望 - 早期乳癌新認知」講座 | 全球華人乳癌組織聯盟 GCBC × 香港聯合腫瘤中心 HKUOC | 2025年10月31日

Dr. Li Yu Chung, Jacky will present a lecture titled "Embracing Hope – New Understanding of Early Breast Cancer" | Global Chinese Breast Cancer Organization Alliance (GCBC) × HKUOC | October 31, 2025

Leave a Comment / breast cancer, Uncategorized /

2025年10月31日（星期五），香港聯合腫瘤中心（HKUOC）臨床腫瘤科李宇聰醫生應邀在全球華人乳癌組織聯盟

Dr. Li Yu Chung, Jacky will present a lecture titled "Embracing Hope – New Understanding of Early Breast Cancer" | Global Chinese Breast Cancer Organization Alliance (GCBC) × HKUOC | October 31, 2025 Read More »

2025年9月18日 宏利健康講座：肺癌、乳癌及前列腺癌治療新趨勢 - 香港聯合腫瘤中心李宇聰醫生分享

Manulife Health Seminar, September 18, 2025: New Trends in the Treatment of Lung Cancer, Breast Cancer, and Prostate Cancer – Dr. Li Yu-chung of the Hong Kong United Oncology Centre shares his insights.

Leave a Comment / breast cancer, prostate cancer, Uncategorized, Lung cancer, Medical lectures /

On September 18, 2025, Dr. Li Yu Chung, Jacky of the Department of Clinical Oncology at the Hong Kong United Oncology Centre (HKUOC) will share the latest treatment trends in lung cancer, breast cancer, and prostate cancer at the Manulife Health Seminar. The seminar will be held at Manulife Tower in Kwun Tong from 10:30 a.m. to 11:30 a.m. All are welcome to attend and learn about the cutting-edge treatment technologies and personalized plans!

Manulife Health Seminar, September 18, 2025: New Trends in the Treatment of Lung Cancer, Breast Cancer, and Prostate Cancer – Dr. Li Yu-chung of the Hong Kong United Oncology Centre shares his insights. Read More »

NCT06966700: Trofuse-032/MK2870-032 Research

Leave a Comment / HER2 gene, Triple negative breast cancer, breast cancer, Breast cancer research, Immunotherapy, Chemotherapy, Genetic testing, Surgery, Uncategorized, Targeted therapy /

Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with high-risk early-stage triple-negative breast cancer (TNBC) or hormone receptor-weak positive/HER2-negative breast cancer, please contact us. We will conduct an initial assessment to determine if you meet the criteria for participation in this clinical trial. Medication and imaging scan costs are fully covered. However, patients must understand the purpose of the study and the potential risks involved.

NCT06966700: Trofuse-032/MK2870-032 Research Read More »

NCT06899126: Destiny-lung 06 Research

Leave a Comment / HER2 gene, Immunotherapy, Chemotherapy, Lung cancer, Platinum-based drugs, Non-small cell lung cancer /

The Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with locally advanced, unresectable, or metastatic HER2-overexpressing non-squamous non-small cell lung cancer with PD-L1 TPS < 50%, please contact us. We will conduct an initial assessment to determine your eligibility for this clinical trial. Medication and imaging scans are free. However, patients must understand the purpose of the study and any potential risks.

NCT06899126: Destiny-lung 06 Research Read More »

2025年10月17日，香港聯合腫瘤中心（HKUOC）聯同香港腫瘤學研究學會（HKOSG）於佐敦盛樂中心成功舉辦「肺癌精準治療 基因檢測改寫生命」講座，吸引超過百位肺癌患者、康復者及家屬參與。主講嘉賓為臨床腫瘤科專科李宇聰醫生，講座深入介紹基因檢測技術如何為肺癌患者帶來新希望。

A new era of precision treatment of lung cancer: Genetic Testing rewrites the Story of life｜Cancer Lecture series (2025/10/17)

Leave a Comment / ALK gene, EGFR gene /

On October 17, 2025, the United Cancer Centre of Hong Kong (HKUOC) and the Hong Kong Society of Oncology Research (HKOSG) successfully held a seminar on "Precision Treatment of Lung Cancer Genetic Testing Rewrites Life" at the Jordan Shing Lok Centre, attracting more than 100 lung cancer patients, survivors and their families to participate. The keynote speaker was Dr. Li Yu Chung, Jacky, a specialist in clinical oncology. The lecture introduced in depth how genetic testing technology can bring new hope to lung cancer patients.

A new era of precision treatment of lung cancer: Genetic Testing rewrites the Story of life｜Cancer Lecture series (2025/10/17) Read More »

DURIGAST試驗FD組與FDT組療效對比數據表格，顯示4個月無進展生存率、中位PFS、客觀緩解率、中位OS及1年以上疾病控制率

Durvalumab consolidates treatment breakthroughs: Significantly prolongs the survival of confined small cell lung cancer

Leave a Comment / Lung cancer, AKT gene, ALK gene, BRAF gene, BRCA gene, CD40 gene, CD73 gene, EGFR gene, EMT gene, ER+/HER2-gene, ESR1 gene, FGFR gene, HER2 gene, HER3 gene, HRAS gene, IDH1 gene, IDHI gene, PD-1 gene, PD-L1 gene, PD-L2 gene, RAS gene, ROS1 gene, Gene classification articles, Targeted therapy /

The third phase of the ADRIATIC study showed that Durvalumab consolidation therapy significantly extended the survival of patients with limited-stage small cell lung cancer (SCLC), with a median total survival of 56 months, which was significantly improved compared to 33 months in the placebo group. This article introduces the research data, clinical significance and treatment prospects in detail to help you understand the latest advances in immunotherapy for lung cancer.

Durvalumab consolidates treatment breakthroughs: Significantly prolongs the survival of confined small cell lung cancer Read More »